Iron management in chronic kidney disease: Conclusions from a "kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference

Iain C. Macdougall; Andreas J. Bircher; Kai Uwe Eckardt; Gregorio T. Obrador; Carol A. Pollock; Peter Stenvinkel; Dorine W. Swinkels; Christoph Wanner; Günter Weiss; Glenn M. Chertow; John W. Adamson; Tadao Akizawa; Stefan D. Anker; Michael Auerbach; Peter Bárány; Anatole Besarab; Sunil Bhandari; Ioav Cabantchik; Alan J. Collins; Daniel W. Coyne; Ángel L.M. De Francisco; Steven Fishbane; Carlo A.J.M. Gaillard; Tomas Ganz; David J. Goldsmith; Chaim Hershko; Ewa A. Jankowska; Kirsten L. Johansen; Kamyar Kalantar-Zadeh; Philip A. Kalra; Bertram L. Kasiske; Francesco Locatelli; Jolanta Małyszko; Gert Mayer; Lawrence P. McMahon; Ashraf Mikhail; Elizabeta Nemeth; Amy Barton Pai; Patrick S. Parfrey; Roberto Pecoits-Filho; Simon D. Roger; Guy Rostoker; Jacques Rottembourg; Ajay K. Singh; Itzchak Slotki; Bruce S. Spinowitz; Der Cherng Tarng; Francesca Tentori; Jorge E. Toblli; Yusuke Tsukamoto; Nosratola D. Vaziri; Wolfgang C. Winkelmayer; David C. Wheeler; Elena Zakharova

doi:10.1016/j.kint.2015.10.002

Iron management in chronic kidney disease: Conclusions from a "kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference

Iain C. Macdougall^*, Andreas J. Bircher, Kai Uwe Eckardt, Gregorio T. Obrador, Carol A. Pollock, Peter Stenvinkel, Dorine W. Swinkels, Christoph Wanner, Günter Weiss, Glenn M. Chertow, John W. Adamson, Tadao Akizawa, Stefan D. Anker, Michael Auerbach, Peter Bárány, Anatole Besarab, Sunil Bhandari, Ioav Cabantchik, Alan J. Collins, Daniel W. CoyneÁngel L.M. De Francisco, Steven Fishbane, Carlo A.J.M. Gaillard, Tomas Ganz, David J. Goldsmith, Chaim Hershko, Ewa A. Jankowska, Kirsten L. Johansen, Kamyar Kalantar-Zadeh, Philip A. Kalra, Bertram L. Kasiske, Francesco Locatelli, Jolanta Małyszko, Gert Mayer, Lawrence P. McMahon, Ashraf Mikhail, Elizabeta Nemeth, Amy Barton Pai, Patrick S. Parfrey, Roberto Pecoits-Filho, Simon D. Roger, Guy Rostoker, Jacques Rottembourg, Ajay K. Singh, Itzchak Slotki, Bruce S. Spinowitz, Der Cherng Tarng, Francesca Tentori, Jorge E. Toblli, Yusuke Tsukamoto, Nosratola D. Vaziri, Wolfgang C. Winkelmayer, David C. Wheeler, Elena Zakharova

^*Corresponding author for this work

Alexander Silberman Institute of Life Sciences

Research output: Contribution to journal › Article › peer-review

218 Scopus citations

Abstract

Before the introduction of erythropoiesis-stimulating agents (ESAs) in 1989, repeated transfusions given to patients with end-stage renal disease caused iron overload, and the need for supplemental iron was rare. However, with the widespread introduction of ESAs, it was recognized that supplemental iron was necessary to optimize hemoglobin response and allow reduction of the ESA dose for economic reasons and recent concerns about ESA safety. Iron supplementation was also found to be more efficacious via intravenous compared to oral administration, and the use of intravenous iron has escalated in recent years. The safety of various iron compounds has been of theoretical concern due to their potential to induce iron overload, oxidative stress, hypersensitivity reactions, and a permissive environment for infectious processes. Therefore, an expert group was convened to assess the benefits and risks of parenteral iron, and to provide strategies for its optimal use while mitigating the risk for acute reactions and other adverse effects.

Original language	English
Pages (from-to)	28-39
Number of pages	12
Journal	Kidney International
Volume	89
Issue number	1
DOIs	https://doi.org/10.1016/j.kint.2015.10.002
State	Published - 1 Jan 2016

Bibliographical note

Publisher Copyright:
© 2016 International Society of Nephrology.

Keywords

chronic kidney disease
hypersensitivity
infections
iron
overload
oxidative stress

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.kint.2015.10.002

Cite this

Macdougall, I. C., Bircher, A. J., Eckardt, K. U., Obrador, G. T., Pollock, C. A., Stenvinkel, P., Swinkels, D. W., Wanner, C., Weiss, G., Chertow, G. M., Adamson, J. W., Akizawa, T., Anker, S. D., Auerbach, M., Bárány, P., Besarab, A., Bhandari, S., Cabantchik, I., Collins, A. J., ... Zakharova, E. (2016). Iron management in chronic kidney disease: Conclusions from a "kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. Kidney International, 89(1), 28-39. https://doi.org/10.1016/j.kint.2015.10.002

@article{5ad7af977547465ea4b39e23e8af3295,

title = "Iron management in chronic kidney disease: Conclusions from a {"}kidney Disease: Improving Global Outcomes{"} (KDIGO) Controversies Conference",

abstract = "Before the introduction of erythropoiesis-stimulating agents (ESAs) in 1989, repeated transfusions given to patients with end-stage renal disease caused iron overload, and the need for supplemental iron was rare. However, with the widespread introduction of ESAs, it was recognized that supplemental iron was necessary to optimize hemoglobin response and allow reduction of the ESA dose for economic reasons and recent concerns about ESA safety. Iron supplementation was also found to be more efficacious via intravenous compared to oral administration, and the use of intravenous iron has escalated in recent years. The safety of various iron compounds has been of theoretical concern due to their potential to induce iron overload, oxidative stress, hypersensitivity reactions, and a permissive environment for infectious processes. Therefore, an expert group was convened to assess the benefits and risks of parenteral iron, and to provide strategies for its optimal use while mitigating the risk for acute reactions and other adverse effects.",

keywords = "chronic kidney disease, hypersensitivity, infections, iron, overload, oxidative stress",

author = "Macdougall, {Iain C.} and Bircher, {Andreas J.} and Eckardt, {Kai Uwe} and Obrador, {Gregorio T.} and Pollock, {Carol A.} and Peter Stenvinkel and Swinkels, {Dorine W.} and Christoph Wanner and G{\"u}nter Weiss and Chertow, {Glenn M.} and Adamson, {John W.} and Tadao Akizawa and Anker, {Stefan D.} and Michael Auerbach and Peter B{\'a}r{\'a}ny and Anatole Besarab and Sunil Bhandari and Ioav Cabantchik and Collins, {Alan J.} and Coyne, {Daniel W.} and {De Francisco}, {{\'A}ngel L.M.} and Steven Fishbane and Gaillard, {Carlo A.J.M.} and Tomas Ganz and Goldsmith, {David J.} and Chaim Hershko and Jankowska, {Ewa A.} and Johansen, {Kirsten L.} and Kamyar Kalantar-Zadeh and Kalra, {Philip A.} and Kasiske, {Bertram L.} and Francesco Locatelli and Jolanta Ma{\l}yszko and Gert Mayer and McMahon, {Lawrence P.} and Ashraf Mikhail and Elizabeta Nemeth and Pai, {Amy Barton} and Parfrey, {Patrick S.} and Roberto Pecoits-Filho and Roger, {Simon D.} and Guy Rostoker and Jacques Rottembourg and Singh, {Ajay K.} and Itzchak Slotki and Spinowitz, {Bruce S.} and Tarng, {Der Cherng} and Francesca Tentori and Toblli, {Jorge E.} and Yusuke Tsukamoto and Vaziri, {Nosratola D.} and Winkelmayer, {Wolfgang C.} and Wheeler, {David C.} and Elena Zakharova",

note = "Publisher Copyright: {\textcopyright} 2016 International Society of Nephrology.",

year = "2016",

month = jan,

day = "1",

doi = "10.1016/j.kint.2015.10.002",

language = "אנגלית",

volume = "89",

pages = "28--39",

journal = "Kidney International",

issn = "0085-2538",

publisher = "Elsevier B.V.",

number = "1",

}

Macdougall, IC, Bircher, AJ, Eckardt, KU, Obrador, GT, Pollock, CA, Stenvinkel, P, Swinkels, DW, Wanner, C, Weiss, G, Chertow, GM, Adamson, JW, Akizawa, T, Anker, SD, Auerbach, M, Bárány, P, Besarab, A, Bhandari, S, Cabantchik, I, Collins, AJ, Coyne, DW, De Francisco, ÁLM, Fishbane, S, Gaillard, CAJM, Ganz, T, Goldsmith, DJ, Hershko, C, Jankowska, EA, Johansen, KL, Kalantar-Zadeh, K, Kalra, PA, Kasiske, BL, Locatelli, F, Małyszko, J, Mayer, G, McMahon, LP, Mikhail, A, Nemeth, E, Pai, AB, Parfrey, PS, Pecoits-Filho, R, Roger, SD, Rostoker, G, Rottembourg, J, Singh, AK, Slotki, I, Spinowitz, BS, Tarng, DC, Tentori, F, Toblli, JE, Tsukamoto, Y, Vaziri, ND, Winkelmayer, WC, Wheeler, DC & Zakharova, E 2016, 'Iron management in chronic kidney disease: Conclusions from a "kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference', Kidney International, vol. 89, no. 1, pp. 28-39. https://doi.org/10.1016/j.kint.2015.10.002

TY - JOUR

T1 - Iron management in chronic kidney disease

T2 - Conclusions from a "kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference

AU - Macdougall, Iain C.

AU - Bircher, Andreas J.

AU - Eckardt, Kai Uwe

AU - Obrador, Gregorio T.

AU - Pollock, Carol A.

AU - Stenvinkel, Peter

AU - Swinkels, Dorine W.

AU - Wanner, Christoph

AU - Weiss, Günter

AU - Chertow, Glenn M.

AU - Adamson, John W.

AU - Akizawa, Tadao

AU - Anker, Stefan D.

AU - Auerbach, Michael

AU - Bárány, Peter

AU - Besarab, Anatole

AU - Bhandari, Sunil

AU - Cabantchik, Ioav

AU - Collins, Alan J.

AU - Coyne, Daniel W.

AU - De Francisco, Ángel L.M.

AU - Fishbane, Steven

AU - Gaillard, Carlo A.J.M.

AU - Ganz, Tomas

AU - Goldsmith, David J.

AU - Hershko, Chaim

AU - Jankowska, Ewa A.

AU - Johansen, Kirsten L.

AU - Kalantar-Zadeh, Kamyar

AU - Kalra, Philip A.

AU - Kasiske, Bertram L.

AU - Locatelli, Francesco

AU - Małyszko, Jolanta

AU - Mayer, Gert

AU - McMahon, Lawrence P.

AU - Mikhail, Ashraf

AU - Nemeth, Elizabeta

AU - Pai, Amy Barton

AU - Parfrey, Patrick S.

AU - Pecoits-Filho, Roberto

AU - Roger, Simon D.

AU - Rostoker, Guy

AU - Rottembourg, Jacques

AU - Singh, Ajay K.

AU - Slotki, Itzchak

AU - Spinowitz, Bruce S.

AU - Tarng, Der Cherng

AU - Tentori, Francesca

AU - Toblli, Jorge E.

AU - Tsukamoto, Yusuke

AU - Vaziri, Nosratola D.

AU - Winkelmayer, Wolfgang C.

AU - Wheeler, David C.

AU - Zakharova, Elena

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Before the introduction of erythropoiesis-stimulating agents (ESAs) in 1989, repeated transfusions given to patients with end-stage renal disease caused iron overload, and the need for supplemental iron was rare. However, with the widespread introduction of ESAs, it was recognized that supplemental iron was necessary to optimize hemoglobin response and allow reduction of the ESA dose for economic reasons and recent concerns about ESA safety. Iron supplementation was also found to be more efficacious via intravenous compared to oral administration, and the use of intravenous iron has escalated in recent years. The safety of various iron compounds has been of theoretical concern due to their potential to induce iron overload, oxidative stress, hypersensitivity reactions, and a permissive environment for infectious processes. Therefore, an expert group was convened to assess the benefits and risks of parenteral iron, and to provide strategies for its optimal use while mitigating the risk for acute reactions and other adverse effects.

AB - Before the introduction of erythropoiesis-stimulating agents (ESAs) in 1989, repeated transfusions given to patients with end-stage renal disease caused iron overload, and the need for supplemental iron was rare. However, with the widespread introduction of ESAs, it was recognized that supplemental iron was necessary to optimize hemoglobin response and allow reduction of the ESA dose for economic reasons and recent concerns about ESA safety. Iron supplementation was also found to be more efficacious via intravenous compared to oral administration, and the use of intravenous iron has escalated in recent years. The safety of various iron compounds has been of theoretical concern due to their potential to induce iron overload, oxidative stress, hypersensitivity reactions, and a permissive environment for infectious processes. Therefore, an expert group was convened to assess the benefits and risks of parenteral iron, and to provide strategies for its optimal use while mitigating the risk for acute reactions and other adverse effects.

KW - chronic kidney disease

KW - hypersensitivity

KW - infections

KW - iron

KW - overload

KW - oxidative stress

UR - http://www.scopus.com/inward/record.url?scp=84973130364&partnerID=8YFLogxK

U2 - 10.1016/j.kint.2015.10.002

DO - 10.1016/j.kint.2015.10.002

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 26759045

AN - SCOPUS:84973130364

SN - 0085-2538

VL - 89

SP - 28

EP - 39

JO - Kidney International

JF - Kidney International

IS - 1

ER -

Iron management in chronic kidney disease: Conclusions from a "kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this